Radiodermatitis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Radiodermatitis – Pipeline Review, H1 2020’, provides an overview of the Radiodermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Radiodermatitis

– The report reviews pipeline therapeutics for Radiodermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Radiodermatitis therapeutics and enlists all their major and minor projects

– The report assesses Radiodermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Radiodermatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Radiodermatitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amryt Pharma Plc

BioCurity Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Foresee Pharmaceuticals Co Ltd

Jay Pharma Inc

KannaLife Sciences Inc

Matrix Biomed Inc

Noveome Biotherapeutics Inc

Regeneus Ltd

RepoCeuticals ApS

Sunny Pharmtech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Radiodermatitis - Overview

Radiodermatitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiodermatitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiodermatitis - Companies Involved in Therapeutics Development

Amryt Pharma Plc

BioCurity Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Foresee Pharmaceuticals Co Ltd

Jay Pharma Inc

KannaLife Sciences Inc

Matrix Biomed Inc

Noveome Biotherapeutics Inc

Regeneus Ltd

RepoCeuticals ApS

Sunny Pharmtech Inc

Radiodermatitis - Drug Profiles

Biologic for Dermatology and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birch bark extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-13019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tempol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZM-241385 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Radiodermatitis - Dormant Projects

Radiodermatitis - Discontinued Products

Radiodermatitis - Product Development Milestones

Featured News & Press Releases

Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Radiodermatitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Radiodermatitis – Pipeline by Amryt Pharma Plc, H1 2020

Radiodermatitis – Pipeline by BioCurity Pharmaceuticals Inc, H1 2020

Radiodermatitis – Pipeline by Daiichi Sankyo Co Ltd, H1 2020

Radiodermatitis – Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020

Radiodermatitis – Pipeline by Jay Pharma Inc, H1 2020

Radiodermatitis – Pipeline by KannaLife Sciences Inc, H1 2020

Radiodermatitis – Pipeline by Matrix Biomed Inc, H1 2020

Radiodermatitis – Pipeline by Noveome Biotherapeutics Inc, H1 2020

Radiodermatitis – Pipeline by Regeneus Ltd, H1 2020

Radiodermatitis – Pipeline by RepoCeuticals ApS, H1 2020

Radiodermatitis – Pipeline by Sunny Pharmtech Inc, H1 2020

Radiodermatitis – Dormant Projects, H1 2020

Radiodermatitis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Radiodermatitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports